About ZEJULA | Zejula® (niraparib)

ZEJULA is the Only Once-Daily Oral PARP Inhibitor1

Description of Treatment

ZEJULA is an inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2, which play a role in DNA repair.

The mean half-life of ZEJULA is 36 hours, allowing for once-daily dosing.

In preclinical studies, ZEJULA-induced cytoxicity was observed in tumor cell lines with or without deficiencies in BRCA1/2.

In vitro studies have shown that ZEJULA-induced cytoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage, apoptosis, and cell death.

Please see Important Safety Information below and full Prescribing Information.

View trial design and results